Floseal® use in dermatologic surgical management of vascular malformations: A novel haemostatic agent in Côte d’Ivoire

Abstract - 451 PDF - 154
Komenan Kassi, Vagamon Bamba, Kouame Kanga, Aang Allou, Alexandre Kouassi, Ildevert Patrice Gbery, Sarah Kourouma, Isidore Kouassi, Elidje Joseph Ecra, Mamadou Kaloga, Abdoulaye Sangare, Pauline Yoboue-Yao, Jean-Marie Kanga

Abstract


A vascular malformation is a congenital growth of artery, venous, capillary or lymphatic vessels leading to functional and aesthetic problems. Although surgical maneuvers allow correction of abnormalities, it poses risk of intra and post-operative blood loss. Sealants have been used during surgical procedures to reduce blood loss. A descriptive study was conducted on a new generation Floseal® to demonstrate its effectiveness to reduce intra and post-operative bleeding during vascular malformation corrective surgery. A group of 19 patients presented with vascular malformations and underwent surgical correction associated with Floseal® use. The mean age of our patients’ was 12.3 years (1 to 33 years). The majority of them (57.6%) were aged between 5 to 15 years. The most common vascular malformation treated was hemangioma (45.5%). Majority of these lesions were located on the head (72.7%). Blood transfusion was not accounted for in any of the cases as average blood loss was 18.18 mL (5 to 70 mL). The average length of hospital stay was 2.4 days. Ten patients (90.9%) were discharged in 2 days after drain was removed. Floseal®, a new generation local haemostatic, is easy to use and efficient to achieve haemostasis for treatment of vascular malformation. Haemostasis was achieved in a short time and blood loss was minimal. However, caution should be taken to reduce allergic reactions and potential viral transmissions, and further study should be done to recommend its use.


Keywords


Vascular malformation; surgery treatment; Floseal® use

Full Text:

PDF

References


Wassef M, Vanwijck R, Clapuyt P, Boon L, Magalon G. Tumeurs et malformations vasculaires, classification anatomopathologique et imagerie (French) [Vascular tumours and malformations, classification, pathology and imaging]. Ann ChirPlastEsthet 2006; 51(4–5): 263–281.doi: 10.1016/j.anplas.2006.07.017.

Boon LM, Vanwijck R. Traitementmédicalet chirurgical des malformations veineuses (French) [Medical and surgical treatment of venous malformations]. Ann ChirPlastEsthet 2006; 51(4–5):403–411. doi: 10.1016/j.anplas.2006.07.023.

Pace G, Suldutto P, Vicentini C,Miano L. Haemostasis in surgery and our experience in enucleo resection of renal cell carcinoma.World J SurgOncol 2010; 8: 37. doi: 10.1186/1477-7819-8-37.

Achneck HE, Sileshi B, Jamiolkowski RM, Aldala DM, Shapiro MLet al. A comprehensive review of topical haemostatic agents; efficacy and recommendations for use. Ann Surg 2010; 251(2): 217–228.doi: 10.1097/SLA.0b013e3181c3bcca.

Reuthebuch O, Lachat ML, Vogt P, Schurr U, TurinaM.FloSeal®: EinneuartigesHämostyptikum in der peripherenGefäßchirurgie (German) [Floseal®: A new haemostyptic agent in peripheral vascular surgery].Vasa 2000; 29(3): 204–206.doi: 10.1024/0301-1526.29.3.204.

Spängier HP, Holle J, Braun F.Gewebeklebungmit Fibrin (German) [Tissue adhesion with fibrin. (An experimental study with rat skin grafts)] Wien KlinWochenschr 1973; 85(50): 827–829.

Echave M, Oyagüez I,Casado MA. Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: A systematic review. BMC Surg2014; 14: 111. doi: 10.1186/1471-2482-14-111.

Yao HHI, Hong MKH, Drummond KJ.Haemostasis in neurosurgery: What is the evidence for gelatin-thrombin matrix sealant? J ClinNeurosci 2013; 20(3):349–356. doi: 10.1016/j.jocn.2012.09.005.

Renkens KL, Payner TD, Leipzig TJ, Feuer H, Morone MA, et al. A multicenter, prospective, randomized trial evaluating a new haemostatic agent for spinal surgery.Spine 2001; 26(15): 1645–1650.doi: 10.1097/00007632-200108010-00002.

Nasso G, Piancone F, Bonifazi R, Romano V, Visicchio G, et al. Prospective, randomized clinical trial of the Floseal® matrix sealant in cardiac surgery. Ann ThoracSurg 2009; 88(5): 1520–1526.doi: 10.1016/j.athoracsur.2009.07.014.

Leixnering M, Reichetseder J, Schultz A, Figl M, Wassermann E, et al. Gelatin thrombin granules for haemostasis in severe traumatic liver and spleen rupture model in swine. J Trauma 2008; 64(2): 456–462.doi: 10.1097/TA.0b013e3180340de1.

Law LW, Chor CM, Leung TY. Use of haemostatic gel in postpartum hemorrhage due to placenta previa. ObstetGynecol2010; 116(2): 528–530.doi: 10.1097/AOG.0b013e3181e772cf.

Lawson JH. The clinical use and immunologic impact of thrombin in surgery. SeminThrombHemost 2006; 32(suppl): 98–110.doi: 10.1055/s-2006-939559.

The CoStasis Multi-center Collaborative Writing Committee. A novel collagen-base composite offers effective haemostasis for multiple surgical indications:Results of randomized controlled trials.Surgery 2001; 129(4): 445–450.doi: 10.1067/msy.2001.112365.

Burnouf T. Modern plasma fractionation.Transfus Med Rev 2007; 21(2): 101–117.doi: 10.1016/j.tmrv.2006.11.001.

Eder G, Neuman M, Cerwenka R, Baumgarten K.Preliminary results of a randomized controlled study on the risk of hepatitis transmission of a two-component fibrin sealant (Tissucol/Tisseel).Fibrin Sealant in Operative Med 1986; 51–59.

Weaver FA, Lew W, Granke K, Yonehiro L, Delange B, et al. A comparison of recombinant thrombin to bovine as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. JVascSurg 2008; 47(6): 1266–1273. doi: 10.1016/j.jvs.2008.01.034.


Refbacks

  • There are currently no refbacks.